Market Scope

Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis

Choose Your Experience

Over 500 Clients, Large & Small from Around the World, Have Trusted Market Scope Data & Analysis

Latest Market Reports

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.

Latest Industry News & Trends

2/22/2024
GlaucomaMeetingNewsletter
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease

Innovative diagnostics for glaucoma screening, staging, and management were a highlight of the Glaucoma 360 New Horizons Forum, with several physicians showcasing new approaches to visual field tes...

2/22/2024
AcquisitionsDeviceNewsletterRetinaSurgical
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition

Carl Zeiss Meditec’s acquisition of DORC (Dutch Ophthalmic Research Center) will change the players in the retinal surgical equipment market, but whether it will lead to any major changes in market...

2/22/2024
LaserNewsletterRefractive
Bausch + Lomb Teneo Excimer Laser Enters US Market After Drought in New Technology
Bausch + Lomb Teneo Excimer Laser Enters US Market After Drought in New Technology

A new excimer laser has entered the US refractive market for the first time in nearly two decades. Bausch + Lomb announced in January that the US FDA had approved the Teneo excimer laser platform f...

2/22/2024
AcquisitionsDealsNewsletterRetina
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front

Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...

2/22/2024
ChinaDry EyeIndustryNewsletter
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets

Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...

2/22/2024
NewsletterRegulation
US FDA Warns of Contamination Risk with Copycat Lumify Eye Drops
US FDA Warns of Contamination Risk with Copycat Lumify Eye Drops

The US FDA issued a warning Jan. 31 to consumers not to purchase or use South Moon, Rebright, or FivFivGo eye drops because of the potential risk of eye infection. The products are copycats that ca...

2/22/2024
IndiaNewsletterRegulation
India Orders Tougher Drug-Making Standards After Overseas Deaths
India Orders Tougher Drug-Making Standards After Overseas Deaths

Prime Minister Narendra Modi’s government has stepped up scrutiny of India’s pharmaceutical factories after being stung by a series of overseas deaths linked to Indian-made drugs. The news agency R...

2/22/2024
GlaucomaLaserNewsletterRefractiveRegulation
Select US FDA Approvals and Clearances in January 2024
Select US FDA Approvals and Clearances in January 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in January 2024, according to the agency’s database. Meridian received clearance for three laser mo...

Provider Surveys & Interviews

Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Table of Innovation

Choose Your Own Adventure

Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.

Safe, Secure & On Any Device

We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.

Pre-Qualified Invitations

We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.

Better Data = Better Decisions

A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.

Market Scope+ App Screen

Market Scope Methodology

A Multi-Step Approach for Accurate & Timely Data

Proprietary data

  • 20+ years of physician survey data
  • Disease models
  • Cultivated database of physicians, ASCs, and hospitals
  • Insight from our team of in-house industry experts

Public data

  • Attendance and participation at major, worldwide meetings
  • Public health systems and registries
  • Clinical study data
  • Analysis of company-published financial reports

Join Market Scope Today

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more

Register A Clinical Account

A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.

Select your country...